Sevoflurane may not be a complete sigh of relief in COVID-19

Kaura, Vikas; Hopkins, Philip M.

doi:10.1016/j.bja.2020.09.012

Cited by 6 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 ). These drugs are used in anaesthesia protocols for patients requiring mechanical ventilation and prolonged, deep sedation to optimize oxygenation and ventilation during respiratory failure from COVID-19 [ [72] , [73] , [74] , [75] ]⁠. Analgesia drugs also form a cluster through their shared action on PTGS1 and PTGS2, also known as cyclooxygenase 1 and cyclooxygenase 2 [ 76 ]⁠.…”

Section: Resultsmentioning

confidence: 99%

Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises

Kanapeckaitė¹,

Mažeikienė²,

Geris³

et al. 2022

Biophysical Chemistry

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises

Kanapeckaitė¹,

Mažeikienė²,

Geris³

et al. 2022

Biophysical Chemistry

View full text Add to dashboard Cite

“…Even so, volatile agents (sevoflurane and isoflurane) are used as alternatives to intravenous sedation in ICUs by an increasing number of physicians [ 51 ] as monotherapy or as part of a combined therapy [ 52 ]. There are some detractors because of volatile agents’ potential adverse events [ 53 ], but there is relevant literature that supports their feasibility and safety of use, without the risk of tolerance or effects on renal or liver function [ 30 , 34 , 45 , 54 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

Sedation with Sevoflurane versus Propofol in COVID-19 Patients with Acute Respiratory Distress Syndrome: Results from a Randomized Clinical Trial

Martínez-Castro,

Monleón,

Puig

et al. 2023

JPM

View full text Add to dashboard Cite

Background: Acute respiratory distress syndrome (ARDS) related to COVID-19 (coronavirus disease 2019) led to intensive care units (ICUs) collapse. Amalgams of sedative agents (including volatile anesthetics) were used due to the clinical shortage of intravenous drugs (mainly propofol and midazolam). Methods: A multicenter, randomized 1:1, controlled clinical trial was designed to compare sedation using propofol and sevoflurane in patients with ARDS associated with COVID-19 infection in terms of oxygenation and mortality. Results: Data from a total of 17 patients (10 in the propofol arm and 7 in the sevoflurane arm) showed a trend toward PaO2/FiO2 improvement and the sevoflurane arm’s superiority in decreasing the likelihood of death (no statistical significance was found). Conclusions: Intravenous agents are the most-used sedative agents in Spain, even though volatile anesthetics, such as sevoflurane and isoflurane, have shown beneficial effects in many clinical conditions. Growing evidence demonstrates the safety and potential benefits of using volatile anesthetics in critical situations.

show abstract

Avoiding kidney damage in ICU sedation with sevoflurane: use isoflurane instead

Sneyd

2022

British Journal of Anaesthesia

View full text Add to dashboard Cite

Sevoflurane may not be a complete sigh of relief in COVID-19

Cited by 6 publications

References 10 publications

Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises

Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises

Sedation with Sevoflurane versus Propofol in COVID-19 Patients with Acute Respiratory Distress Syndrome: Results from a Randomized Clinical Trial

Avoiding kidney damage in ICU sedation with sevoflurane: use isoflurane instead

Contact Info

Product

Resources

About